Illumina/$ILMN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Illumina
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Ticker
$ILMN
Sector
Primary listing
Employees
9,000
Headquarters
Website
Illumina Metrics
BasicAdvanced
$15B
12.07
$7.91
1.43
-
Price and volume
Market cap
$15B
Beta
1.43
52-week high
$156.66
52-week low
$68.70
Average daily volume
1.6M
Financial strength
Current ratio
1.808
Quick ratio
1.27
Long term debt to equity
89.46
Total debt to equity
115.058
Interest coverage (TTM)
7.75%
Profitability
EBITDA (TTM)
1,138
Gross margin (TTM)
68.16%
Net profit margin (TTM)
29.34%
Operating margin (TTM)
18.04%
Effective tax rate (TTM)
9.89%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
7.94%
Return on equity (TTM)
68.06%
Valuation
Price to earnings (TTM)
12.068
Price to revenue (TTM)
3.532
Price to book
6.64
Price to tangible book (TTM)
16.52
Price to free cash flow (TTM)
14.675
Free cash flow yield (TTM)
6.81%
Free cash flow per share (TTM)
6.505
Growth
Revenue change (TTM)
-3.27%
Earnings per share change (TTM)
-141.19%
3-year revenue growth (CAGR)
-2.99%
10-year revenue growth (CAGR)
7.54%
3-year earnings per share growth (CAGR)
294.73%
10-year earnings per share growth (CAGR)
9.22%
What the Analysts think about Illumina
Analyst ratings (Buy, Hold, Sell) for Illumina stock.
Bulls say / Bears say
Illumina’s forecast for 2025 revenue, between $4.28 billion and $4.40 billion, is below the Wall Street consensus of $4.39 billion. This miss led to nearly a 4% drop in the company’s shares in after-hours trading, highlighting difficulties in meeting market expectations (Reuters turn6news12).
On March 4, 2025, China banned imports of Illumina’s genetic sequencing machines, which make up about 7% of its total sales. Illumina responded by cutting $100 million in costs and reducing its EPS forecast to $4.50, emphasizing significant regulatory risks in an important market (Reuters turn2news13).
Illumina’s shares have dropped by almost 36% year-to-date due to trade tensions, tight funding, and ongoing market challenges, reflecting ongoing worries among investors about the company’s growth outlook and international risks (WSJ turn5news12).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Illumina Financial Performance
Revenues and expenses
Illumina Earnings Performance
Company profitability
Illumina News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Illumina stock?
Illumina (ILMN) has a market cap of $15B as of October 19, 2025.
What is the P/E ratio for Illumina stock?
The price to earnings (P/E) ratio for Illumina (ILMN) stock is 12.07 as of October 19, 2025.
Does Illumina stock pay dividends?
No, Illumina (ILMN) stock does not pay dividends to its shareholders as of October 19, 2025.
When is the next Illumina dividend payment date?
Illumina (ILMN) stock does not pay dividends to its shareholders.
What is the beta indicator for Illumina?
Illumina (ILMN) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.